Stock Markets April 21, 2026 02:53 AM

Beiersdorf Q1 Sales Fall Short as NIVEA Slump Offsets Strong Derma Growth

Group organic sales decline 4.6% to roughly €2.5bn; Derma rises but NIVEA weakness drags results below forecasts

By Caleb Monroe
Beiersdorf Q1 Sales Fall Short as NIVEA Slump Offsets Strong Derma Growth

Beiersdorf reported first-quarter organic sales that were weaker than analysts and the company had expected, with a 4.6% year-on-year decline to about €2.5 billion. A 7.0% drop at the mass skincare brand NIVEA offset an 8.2% rise in the Derma business, leaving overall results behind consensus and Jefferies estimates despite the company reiterating its full-year outlook.

Key Points

  • Group organic sales decreased 4.6% year-on-year to about €2.5 billion, missing consensus and Jefferies estimates - impacts equity markets and consumer goods sector.
  • NIVEA sales fell 7.0%, driving a larger-than-expected decline in the consumer division, while the Derma unit grew 8.2% and outperformed market expectations - impacts skincare and healthcare-focused consumer subsectors.
  • Beiersdorf reiterated full-year guidance with organic sales expected to be flat to slightly up and operating margins seen slightly below last year's level - impacts investor expectations and corporate margin outlooks.

Beiersdorf reported a weaker-than-expected performance in the first quarter, with group organic sales falling 4.6% year-on-year to about 2.5 billion euros. That outcome missed both consensus forecasts for a 3.1% decline and Jefferies' estimate of a 3.8% drop. The company had earlier guided to a low single-digit decline for the period.

The consumer division recorded a 4.7% organic downturn, larger than the roughly 3.5% fall anticipated by the market. Within that division, sales at the core NIVEA brand were down 7.0%, underscoring persistent weakness in the mass skincare segment.

By contrast, Beiersdorf's Derma unit - which includes brands such as Eucerin and Aquaphor - expanded by 8.2% organically, outpacing expectations of about 7% growth and beating a low single-digit market. The La Prairie luxury brand saw sales decline 14.9%, a drop that was marginally less severe than some forecasts had suggested.

Jefferies analysts said the results were "way shy" of expectations, pointing to a particularly weak March and raising concerns about the credibility of the company's guidance.

Despite the shortfall in quarterly sales, Beiersdorf reiterated its full-year guidance. The company continues to expect organic sales to be flat to slightly up for the year - compared with consensus around 0.6% - while forecasting operating margins that are slightly below last year's level.

Analysts flagged that prolonged weakness at NIVEA could force strategic responses from management. Specifically, sustained softness in the mass skincare business may necessitate pricing moves or higher marketing spending to stabilise demand. Market sentiment has been pressured as the stock trades near 10-year lows.

The quarter presented a mixed picture: strong dermatology momentum helped offset some of the pressure from mass-market skincare, but the aggregate result fell short of street expectations. Investors and industry watchers will likely follow upcoming quarters closely to see whether the Derma unit's outperformance can offset continued declines at NIVEA, and whether management adjusts pricing or promotional tactics in response.

Key financial metrics reported for the quarter included the group's 4.6% organic sales decline to about 2.5 billion euros, the consumer division's 4.7% drop, NIVEA's 7.0% fall, Derma's 8.2% growth, and La Prairie's 14.9% decline.

Risks

  • Sustained weakness at NIVEA could require pricing adjustments or higher marketing investment, which would affect margins and promotional dynamics in the consumer goods sector.
  • Market doubts about the credibility of company guidance following a weak March could weigh on investor confidence and share price performance in the cosmetics and personal-care equity segment.
  • The stock trading near 10-year lows suggests heightened market sensitivity to continued underperformance, posing a risk to shareholder value in the short term.

More from Stock Markets

Roche Q1 Sales Fall 5% as Currency Headwinds Offset Drug Gains Apr 23, 2026 XP Power posts strongest quarterly orders since 2022 as demand rebounds Apr 23, 2026 London Stock Exchange Group Lifts Full-Year Outlook After Strong Q1 Performance Apr 23, 2026 Hikma Sticks to 2026 Guidance as Divisions Deliver in Q1 Apr 23, 2026 Man Group Q1 AUM Misses Street as Major Single-Client Redemption Hits Systematic Book Apr 23, 2026